More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.

To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:

§  Type of product

§  Ophthalmic API

§  Ophthalmic drug FDF

§  Type of FDF manufactured

§  Solid

§  Semi-solid

§  Liquid / suspension

§  Type of primary packaging

§  Ampoule / vial 

§  Glass / plastic bottle

§  Ointment tube

§  Blister packing

§  Other forms

§  Scale of manufacturing

§  Clinical

§  Commercial

§  Company size

§  Small

§  Mid-sized

§  Large

§  Very large

§  Target disease indication

§  Age-related macular degeneration

§  Dry eye

§  Glaucoma

§  Other disease segments

§  Key geographical regions

§  North America (US, Canada and Mexico)

§  Europe (UK, Germany, France, Spain, Italy and rest of Europe)

§  Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)

§  Rest of the world

The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain:

§  Akorn

§  Akums

§  Bal Pharma

§  Catalent

§  Cayman Chemical

§  Entod Pharmaceuticals

§  Farmigea

§  Glenmark Pharmaceuticals

§  Indiana Ophthalmics

§  Lomapharm

§  Medichem

§  Pillar5 Pharma

§  Recipharm

§  Salvat

§  Sterling Pharmaceutical Services

§  Sunways India

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Competitiveness Analysis

6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles

7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles

8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles

9. Clinical Trial Analysis

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies

14. SWOT Analysis

15. Survey Analysis

16. Executive Insights

17. Future Growth Opportunities

18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers

19. Appendix 2: Tabulated Data

20. Appendix 3: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com